BPC-157 vs IGF-1 LR3
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
BPC-157
Body Protection Compound-157 is a synthetic peptide derived from a protein found in human gastric juice. It has shown remarkable healing properties in research studies.
Full details →IGF-1 LR3
IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is a modified version of IGF-1 with extended half-life and enhanced potency. The modifications prevent binding to IGF binding proteins, increasing bioavailability.
Full details →Side-by-Side Comparison
| Aspect | BPC-157 | IGF-1 LR3 |
|---|---|---|
| Dose Range | 250 mcg–500 mcg | 20 mcg–100 mcg |
| Frequency | 2x daily | 1x daily |
| Cycle Length | 4–6 weeks | 4–6 weeks |
| Route | subcutaneous | subcutaneous |
| Mechanism | BPC-157 works through multiple pathways including upregulation of growth factor expression, nitric oxide system modulation, and promotion of angiogenesis. It enhances tendon-to-bone healing and supports the formation of new blood vessels. | Binds to IGF-1 receptors to promote protein synthesis, muscle growth, and fat metabolism. The LR3 modification (13 amino acid extension and arginine substitution) extends half-life from minutes to 20-30 hours. |
| Typical Dosage | Typical research dosages range from 250-500mcg administered 1-2 times daily. Both subcutaneous and oral administration have been studied. | Research protocols typically use 20-100mcg daily, often divided into multiple injections or administered bilaterally to target muscles. |
| Administration | Can be administered subcutaneously near the injury site or systemically. Stable in gastric juice, making oral administration viable. | Intramuscular injection (site-specific growth) or subcutaneous for systemic effects. Often cycled 4-6 weeks on, equal time off. |
| Side Effects | Generally well-tolerated in research. Some reports of mild nausea or dizziness at higher doses. | Hypoglycemia, joint pain, water retention, potential jaw/hand growth with extended use, and injection site reactions. |
| Best For |
What They Have in Common
BPC-157, IGF-1 LR3 are both commonly used for:
Key Differences
Unique to IGF-1 LR3:
Which Has Stronger Evidence?
- Muscle Growth: IGF-1 LR3 has stronger research support.
- Recovery & Healing: BPC-157 has stronger research support.
| Goal | BPC-157 | IGF-1 LR3 |
|---|---|---|
| Muscle Growth | medium | high |
| Recovery & Healing | high | medium |
Key Studies
BPC-157
- Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.
HSS journal : the musculoskeletal journal of Hospital for Special Surgery, 2025
- Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing.
Current reviews in musculoskeletal medicine, 2025
- Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study.
Alternative therapies in health and medicine, 2024
IGF-1 LR3
- IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep.
American journal of physiology. Endocrinology and metabolism, 2025
- Revolutionary decellularized Alstroemeria stem-based nerve conduit integrated with GelMA and controlled IGF-1 LR3 release for enhanced rat sciatic nerve regeneration.
International journal of biological macromolecules, 2025
- Attenuated glucose-stimulated insulin secretion during an acute IGF-1 LR3 infusion into fetal sheep does not persist in isolated islets.
Journal of developmental origins of health and disease, 2023
Ready to Learn More?
Looking for trusted sources?